Skip to main content
Premium Trial:

Request an Annual Quote

French Plant Breeding Firm Meiogenix Raises $13M in Series A Round

NEW YORK — French plant breeding firm Meiogenix said on Tuesday that it has raised $13 million in a Series A financing round.

The round was led by Sofinnova Partners and included Genoa Ventures, Bpifrance, Casdin Capital, and Alexandria Venture Investments.

Meiogenix is developing gene- and chromosome-editing technologies designed to accelerate plant biodiversity by mixing parental genomes during reproduction. This approach, the company said, can speed plant variety selection, reverse the loss of biodiversity from systematic crop selection, and improve agronomic traits such as taste and nutritional content.

"The Series A funding will provide capital for our implementation in the United States and further product development," Meiogenix CEO Luc Mathis said in a statement.

In early 2020, Meiogenix began working with Bayer to develop plant breeding and genome editing technologies. Around the same time, the company partnered with Cornell to improve maize.

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.